



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 3/10 (2006.01)
A61K 31/4045 (2006.01) A61P 5/50 (2006.01)

(21) International Application Number:

PCT/US2022/043383

(22) International Filing Date:

13 September 2022 (13.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/243,666 13 September 2021 (13.09.2021) US
63/318,363 09 March 2022 (09.03.2022) US

(71) Applicant: **PROVENTION BIO, INC.** [US/US]; 55
Broad Street, 2nd Floor, Red Bank, New Jersey 07701 (US).

(72) Inventor: **LEON, Francisco**; 8501 River Rock Terrace,
Bethesda, Maryland 20817 (US).


(74) Agent: **DYKEMAN, David J.** et al.; Greenberg Traurig,
LLP, One International Place, Suite 2000, Boston, Massa-
chusetts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS AND COMPOSITIONS COMPRISING ANTI-CD3 ANTIBODIES AND DYRK1A INHIBITORS FOR
TREATING DIABETES

FIG. 1



(57) Abstract: Provided herein are methods and compositions for treating type 1 diabetes. Also provided herein are methods and compositions for preventing or delaying the onset of type 1 diabetes. In some embodiments, such method can include administering to a subject in need thereof a 12-day to 14-day course of teplizumab at a total dose of about 9000 $\mu\text{g}/\text{m}^2$ to about 14000 $\mu\text{g}/\text{m}^2$ and administering an effective amount of a DYRK1A inhibitor.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*